RxDoctor Payments Data

Molly Parker, DO

Family Medicine · Jonesville, MINPI 1992074231

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $19,490 of the $24,009 with a category attached, or 81.2%. Boehringer Ingelheim accounts for 95.5% of it on its own, with 17 other manufacturers making up the rest. Among family medicine clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$24,009in general payments, 2019–2025

Across 103 payments — averaging $233.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$23K
  • Novo Nordisk$256
  • Johnson & Johnson$227
  • AbbVie$161
  • Actelion Pharmaceuticals US, Inc.$72
  • Dexcom, Inc.$65
  • plus $293 from 12 others

What the payments were for

  • Consulting fees$19,49081%
  • Travel & lodging$3,23213%
  • Food & beverage$1,2875%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$24,009 in reported general payments places this provider in the 95th percentile of 3,945 family medicine providers in Michigan.

See all family medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$36,123
Medicare patients
105
Services billed
426

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter39$31,644
XareltoRivaroxaban19$29,345
OzempicSemaglutide26$24,235
FarxigaDapagliflozin Propanediol22$23,415
EliquisApixaban16$14,392
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog16$12,141
Breo ElliptaFluticasone/Vilanterol24$11,796
TrulicityDulaglutide12$11,062
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr13$6,070
Levothyroxine Sodium283$3,848
Atorvastatin Calcium252$3,682
Arnuity ElliptaFluticasone Furoate11$2,228
Bupropion XlBupropion Hcl46$2,170
Losartan Potassium154$2,136
Metoprolol Succinate123$1,937

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$227$29,34519 claims
Novo NordiskOzempic$256$24,23526 claims
AstraZenecaFarxiga$12$23,41522 claims
Lilly USA, LLCTrulicity$53$11,06212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,945 family medicine providers in Michigan.

Other family medicine in Jonesville

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →